Lysophospholipids are lipid molecules that are receiving growing attention because, in addition to their structural function in the cell membrane, they are now regarded as important regulators for diverse biological functions through activation of specific receptors. These receptors have been characterized during the last two decades as G protein-coupled receptors (GPCRs) and, among them, two families stand out: lysophosphatidic acid (LPA 1-6 ) and sphingosine 1-phoshate (S1P 1-5 ) receptors. Despite their interest, the high structural similarity between them has restrained the development of selective and high affinity ligands and therefore the elucidation of the role of these receptors in the central nervous system (CNS). This review provides an overview about the different LPA receptors with a special focus on the LPA 1 subtype from a medicinal chemistry perspective. It summarizes the most recent developments in the search for selective and specific agonists and antagonists of the LPA 1 receptor and highlights their current status in the drug development pipeline.
Introduction
The phospholipid superfamily has been traditionally linked to structural roles, as key constituents of biological membranes. Nevertheless, research from the last decades has associated some phospholipids with diverse signalling functions, reporting their action as extracellular signals and, moreover, their involvement in many physiological and pathological processes.
1,2
Phospholipids are usually divided into two broad families: (i) glycerophospholipids, 3 which are structurally based on the glycerol scaffold (Fig. 1A ) and (ii) sphingophospholipids, which are derivatives of the amino alcohol sphingosine (Fig. 1B ). They present a polar head bearing a phosphate group (-OPO 3 Y À , Y ¼ H, choline, ethanolamine, Fig. 1A and B) and two hydrophobic chains (R, X, Fig. 1A and B). When one of the fatty acid chains is missing (X ¼ H, Fig. 1A and B), the resulting derivatives are denominated lysophospholipids. These molecules are quantitatively minor lipid species compared to their parent compounds, the phospholipids -which have a major presence in cell membranes. Despite their low concentration, lysophospholipids are important because of their ability to signal through G protein-coupled receptors (GPCRs). Lysophosphatidic acid (LPA, 1-acyl-sn-glycero-3-phosphate, Fig. 1C ) and sphingosine 1-phosphate 3 (S1P, Fig. 1D ) are the two most prominent molecules of this family, which are being extensively studied and their biological activities have been shown to be extremely relevant.
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Although they belong to distinct signalling systems, similarities between these two lipids extend to their tissue distribution and concentration, homology and effector pathways of their cognate receptors, and the broad range of their biological roles. In contrast, the actions of other lysophospholipids have not been elucidated to such a high degree and very little is known about their endogenous receptors. However, recent in vitro studies suggest that they can induce various and unique cellular responses.
5
Among the bioactive phospholipids, LPA stands out as a molecule that elicits a plethora of biological effects, both in the central nervous system (CNS) and in the periphery, by acting on at least six different receptors. Nonetheless, its therapeutic potential is still far from being established given the complexity of the system and the lack of specic ligands, agonists and antagonists, that enable the elucidation of the (patho)physiological roles played by a particular LPA receptor subtype. This review summarizes the most important aspects of the LPA signaling system with a special focus on the LPA 1 receptor, its ligands and their potential for drug development. In the rst part, we provide an overview of the different LPA receptors with particular attention to the LPA 1 subtype, its endogenous ligand LPA, and the main (patho)physiological functions regulated by the LPA 1 receptor. Although more exhaustive reviews have been published on the molecular, biochemical and pharmacological aspects of the complex LPA system (see references), this introduction will allow us to proceed to the second part of the review, in which we address, from a medicinal chemistry perspective, the most essential advances reported so far regarding the development of selective and specic ligands of the LPA 1 receptor. Finally, we will summarize the current status and the clinical perspectives of the compounds that have progressed most in the drug development pipeline.
Lysophosphatidic acid receptors
LPA has a well-known structural function as a precursor and a metabolite in the biosynthesis of membrane phospholipids. However, it was not until the 1960s that several groups started to report biological actions mediated by LPA, such as smooth muscle contraction and platelet aggregation. 6 Nevertheless, the specic function of this intriguing molecule was still unknown.
During the mid-1980s, proliferative LPA-dependent effects in broblasts were described. These responses were completely inhibited with pertussis toxin pre-treatment, which specically inactivates G ai/o -type G proteins. 7 This was followed by the description in the early 1990s of several morphological cell changes attributed to LPA, such as cell growth, cell rounding/ neurite retraction 8, 9 and actin stress ber formation. 10 At the same time, S1P was reported to evoke cellular responses similar to those induced by LPA, suggesting that they might even share the same GPCRs.
11
Growing evidence was making clear that LPA was acting through a GPCR, as it was nally demonstrated by van Blitterswijk 12 through photoaffinity labeling experiments, which revealed [
32 P] LPA-binding membrane proteins of 38-40 kDa present in various LPA-responsive cell types and in the brain. This binding protein met all the pharmacological criteria for a specic, high-affinity LPA receptor since its labeling was competitively and specically inhibited by unlabeled LPA with an IC 50 as low as 10 nM. In addition to the LPA responses, LPA binding was not detectable in LPA-unresponsive cells such as human neutrophils, and was blocked by suramin, a known inhibitor of LPA actions. Although similar evidences were shown independently by Clark, 13 the biophysical properties of LPA or the possibility of second messenger activities were also proposed as alternative mechanisms for LPA actions, and this ambiguity persisted in the absence of molecularly identied receptors.
Finally, in 1996, Chun and coworkers reported the discovery of the rst lysophospholipid receptor gene, ventricular zone gene 1 (vzg-1), 14 during their studies on mammalian neurogenesis. Vzg-1 encoded a GPCR that had the properties of a high-affinity LPA receptor. Identication of this gene as encoding an LPA receptor was independently demonstrated by Goetzl 15 and Kiefer. 16 Denitive conrmation about the identity of this receptor was achieved by heterologous expression in mammalian cells 17 and genetic deletion of the receptor.
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Similar approaches allowed the identication of new receptors, like the rst receptor for S1P, which was independently reported by two groups in 1998. 19, 20 Since then, several members of the orphan GPCR receptor family called "endothelial differentiation genes" (Edg) were identied as GPCRs for both LPA and S1P, including Edg4 (LPA 2 ), 21, 22 Edg7 (LPA 3 ), 23 Edg5 (S1P 2 ), Edg3 (S1P 3 ), Edg6 (S1P 4 ) 24 and Edg8 (S1P 5 ). 25 Regarding the LPA receptors, another group of less similar GPCR genes have also been identied, which are GPR23 (LPA 4 ), 26, 27 GPR92 (LPA 5 ), 28, 29 and P2Y5 (LPA 6 ). 30, 31 This latter group is more closely related to the family of P2Y purinergic receptor genes, indicating that LPA receptors have evolved via two distinct lineages in the rhodopsin GPCR family. To date, a total of eleven receptors have been described, six for LPA (LPA [1] [2] [3] [4] [5] [6] ) and ve for S1P (S1P [1] [2] [3] [4] [5] ). The current nomenclature includes the cognate ligand and the chronological order of identication. All LPA receptors are type I, rhodopsin-like GPCRs that differ in their tissue distribution and downstream signalling pathways 32 (see Fig. 2 and Table 1 for a summary of some relevant features).
LPA 1 receptor
The mammalian LPAR1 gene encodes a $41 kDa protein of 364 amino acids with seven putative transmembrane domains. Human LPAR1 is widely expressed in the heart, brain, placenta, skeletal muscle, kidney, pancreas, spleen, prostate, testis, ovary, small intestine and colon. 33 A similar distribution is observed for the Lpar1 mouse gene, although it is more spatially restricted during embryogenesis, where it is mainly found in the ventricular zone (VZ), a major site for neuroprogenitor cell proliferation during prenatal developmental stages. VZ disappears prior to birth, reappearing during the postnatal life within oligodendrocytes and Schwann cells that may inuence myelination in the central and peripheral nervous system, indicating roles for LPA signalling in cortical development.
34
Signalling through LPA 1 receptor induces a range of cellular responses: cell proliferation and survival, cell migration and cytoskeletal changes. At the molecular level, LPA 1 receptor activation can be transduced through three types of G proteins: G ai/o , G aq/11 , and G a12/13 , that are responsible for Ca 2+ mobilization, adenylyl cyclase inhibition and activation of phospholipase C, Akt, Rho and mitogen-activated protein kinase pathways. The targeted disruption of Lpar1 in mice revealed unanticipated in vivo functions of this receptor. Lpar1À/À mice show 50% perinatal lethality and survivors have a reduced body size, craniofacial dysmorphism, and increased apoptosis in sciatic nerve Schwann cells.
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Other LPA receptors Together with the LPA 1 receptor, LPA 2 and LPA 3 have been the most thoroughly studied ones. The expression pattern of the LPA 2 receptor is more spatiotemporally restricted compared to the LPA 1 receptor. Lpar2 is found in the embryonic brain, but its expression strongly attenuates one week aer birth. In humans, LPAR2 is found in the testis, leukocytes, prostate, spleen, thymus and pancreas.
32 LPA 2 null mice 35 were born normally and showed no obvious behavioural, anatomical or histological abnormalities, in contrast to LPA 1 null mice. 35 When LPA 1 /LPA 2 double-null mice were generated, aggravation of the phenotypic abnormalities was expected, as LPA 2 is coexpressed with LPA 1 in several organs and cells and thus a major loss of LPA signalling would be achieved. However, no qualitative differences in phenotypes, compared to LPA 1 null mice, were observed. Thus, LPA 1 and LPA 2 receptors may have redundant functions in LPA signalling.
LPAR3 encodes an $40 kDa GPCR broadly expressed in humans. This receptor shows a strong preference for unsaturated chains and has a relatively high affinity for 2-acyl-LPA containing unsaturated fatty acids. Despite the fact that LPA 3 is expressed in the frontal cortex, hippocampus, and amygdala, no phenotypes related to LPA 3 loss in the nervous system have been reported to date.
32,43
The LPA 4 receptor is structurally distinct from classical LPA [1] [2] [3] and S1P receptors that share signicant homology, and is more closely related to P2Y purinergic receptors. It does not, however, respond to any nucleotide or nucleoside tested. LPA 4 is ubiquitously expressed in both humans and mice and it is speci-cally abundant in the ovary. LPA 5 (GPR92) was identied by two independent groups in 2005 from the receptor gene data bank. This receptor is structurally different to LPA [1] [2] [3] , but shares 35% homology with LPA 4 . Lpar5 is relatively broadly expressed in murine and human tissues.
The orphan receptor P2Y5, closely related to the purinergic family and sharing high homology with LPA 4 receptor, has been recently classied as the LPA 6 receptor. 31 This receptor has been found to be essential for the maintenance of hair growth.
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Recently other receptors have been proposed. GPR87 and P2Y10 are orphan GPCRs that have been described to be responsive either to LPA or to both LPA and S1P, respectively. They belong to the P2Y family and are similar to LPA 4 and LPA 5 receptors.
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Among all LPA actions, those elicited through LPA [1] [2] [3] receptors have been the most studied to date, revealing crucial roles in the nervous, vascular, immune and reproductive systems. Focusing on the CNS, LPA 1 is described as the receptor with a major expression and, even though, the information is very scarce, there is evidence enough to suggest that it can contribute to the pathogenesis of several diseases and, accordingly, could be endowed with therapeutic relevance for the treatment of CNS disorders.
Lysophosphatidic acid receptor structure
Currently, no crystal structures have been elucidated for any native LPA receptor. The only phospholipid GPCR crystal structure available is the structure of S1P 1 , 38 which has provided valuable information about the receptor-ligand interaction of this type of receptor.
39 This is especially useful for molecular modelling of LPA receptors, because they share much higher sequence homology with this receptor than with any of the other currently available GPCR crystal structures, a fact that will enable the construction of homology models of LPA 1-3 receptors using the structure of the S1P 1 receptor as the template.
40
Mutagenesis studies combined with computational analysis identied several important residues in LPA 1-3 receptors, most of them located in transmembrane domains. 41, 42 In this regard, Arg3.28 is important for efficacy and potency for all three receptors, as it forms a salt bridge with the phosphate group while Gln3.29 interacts with the hydroxy group of LPA. Thus, this latter position is responsible for LPA/S1P selectivity, as S1P receptors bear glutamic acid instead. These two residues are conserved over the LPA [1] [2] [3] receptors, together with Trp4.64, which, in contrast, is only implicated in LPA 3 activation. Other amino acids important for ligand recognition and selectivity among the LPA 1-3 and S1P receptors are found in positions 5.38 (Asp in LPA 1 ) and 7.36 (Lys in LPA 1 ), though their function is still not clear. LPA 4 and LPA 5 share less amino acid identity with LPA [1] [2] [3] , and detailed models of their interaction with LPA are not available. Most of the residues described above are not present in LPA 4 and LPA 5 , suggesting that these receptors have different ligand binding characteristics. Further research is needed to identify the critical residues for these receptors, and this information will need to be re-evaluated once crystal structure data become available.
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Biosynthesis and degradation of LPA LPA is generally known as a mixture of various lysophospholipids with both saturated (16 : 0, 18 : 0) and unsaturated (16 : 1, 18 : 1, 18 : 2, 20 : 4) fatty acid chains. It must be noted that in the context of LPA as a signalling molecule, and thus throughout this review, LPA refers to 1-oleoyl-sn-glycero-3-phosphate. It is found in almost all eukaryotic tissues and biological uids, including blood.
32 Among them, serum is the best characterized source of LPA, where it is bound to albumin and other proteins, probably preventing the molecule from rapid degradation.
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Autotaxin (ATX), 45, 46 a secreted glycoprotein with lysophospholipase D activity, is the primary enzyme responsible for LPA production in blood. In fact, ATX heterozygote knockout mice have a 50% reduction of circulating LPA compared to wild type mice 47 and negligible levels of LPA are detected aer treatment with ATX inhibitors. 48 Outside the cell, the enzyme ATX converts lysophosphatidylcholine (LPC), produced from different membrane phospholipids via phospholipase A 2 (PLA 2 ), into LPA (Fig. 3) .
Degradation of LPA can occur through two main routes. In the rst one, LPA is irreversibly dephosphorylated to monacylglycerol by lipid phosphate phosphohydrolases, presumably LPP1. In the second route, LPA is reversibly esteried to phosphatidic acid (PA) by the enzyme LPA-acyltransferase (LPAAT).
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Physiological roles of the LPA 1 receptor and therapeutic potential LPA displays a wide range of cellular effects through its receptors. Among the most important actions of LPA, those mediated by the LPA 1 receptor in the CNS stand out, a fact that immediately suggests a potential for the treatment of related diseases.
Nervous system
As highlighted before, the nervous system is one of the major locations for LPA receptors, 34 as they are expressed in most of its cell types under physiological and pathological conditions. In addition, LPA can be found in the brain in high concentrations, inuencing many developmental processes and neurological disorders.
Among the different LPA receptors, the LPA 1 subtype is the most abundant one in the brain, 32 where it plays a major role in the development of the embryonic brain and thus in neurogenesis, due to its main expression in the VZ of the embryonic brain. Neural progenitor cells (NPCs) -the differentiable cells responsible for neurogenesis -express LPA 1-3 receptors and are found in this area, where they proliferate and sequentially differentiate into various cell types, such as neurons, astrocytes or oligodendrocytes.
Several in vitro and in vivo studies have demonstrated that LPA controls proliferation and differentiation of NPCs via LPA 1 . Furthermore, LPA 1 null NPCs do not present the ability to achieve LPA-dependent neurogenesis-related changes, conrming LPA 1 as a modulator of neurogenesis. In adult neurons, LPA is known to inuence neuronal survival/death processes. Moreover, it has been described that LPA 1 is related to neuroprotection, as apoptotic cell death is described in LPA 1 null mouse brains.
34
Neuropsychiatric disorders, like schizophrenia, anxiety, memory impairment or Alzheimer's disease, have been recently linked to LPA signalling. LPA 1 null mutants share schizophrenia-type defects, such as pre-pulse inhibition, serotonin synthesis alteration or cranial dysmorphism. In addition, LPA signalling through LPA 1 in the hippocampus modulates neurogenesis, which is related to learning and emotional behaviour; and memory impairments have been reported in LPA 1 decient mice.
Two important developmental disorders linked to the LPA 1 receptor are: fetal hypoxia and fetal hydrocephalus. It was shown that mouse brains exposed to LPA develop fetal hydrocephalus, and that treatment with an LPA 1 antagonist blocked this response, demonstrating the implication of the receptor.
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Regarding fetal hypoxia, it has been described that the absence of the adequate supply of oxygen causes cortical disorganization throughout NPCs via over-activation of the LPA 1 receptor.
51
Since both diseases are associated with later development of CNS disorders, such as epilepsy, schizophrenia or autism, it is clear that LPA 1 signalling needs to be tightly regulated to ensure unaltered brain functions. LPA 1 has also been associated with myelination because its expression in oligodendrocytes (CNS myelinating cells) correlates spatiotemporally with their maturation and myelination, and it has been shown that LPA inuences several of its cellular responses. Moreover, a recent study has shown that LPA, acting through the LPA 1 receptor, promotes Schwann cell migration, which precedes myelination and remyelination in the peripheral nervous system.
52
It has been suggested that LPA plays a key role in the initiation of neuropathic pain, a form of chronic pain which accounts for almost 20% of its diagnosed cases in the U.S.A. Neuropathic pain is the result of a combination of multiple factors, but a direct link with ber demyelination has been reported. 53 LPA produces nerve injury via LPA 1 -mediated demyelination with subsequent loss of the structural and functional integrity of neurons. In further support of this, LPA 1 decient mice do not show neuropathic pain behaviour or demyelination in response to intrathecal LPA injection or nerve injury. LPA 5 null mice are also protected from developing neurophatic pain, although the mechanisms involved are different from those mediated by LPA 1 .
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Peripheral roles of the LPA 1 receptor
The main peripheral roles of LPA characterized so far are related to the ability of this molecule to inuence cellular proliferation and differentiation in several tissues and systems. In this regard, LPA performs an important role in the vascular system, where it modulates different effects in vascular smooth muscle cells (VSMCs) and vascular endothelial cells (VECs), which are involved in processes like angiogenesis (the formation of new capillary networks from pre-existing vasculature by sprouting and/or splitting of capillaries) or vascular maturation. Angiogenesis involves coordinated proliferation, migration, adhesion, differentiation, and assembly of both VECs and their surrounding VSMCs, and its dysregulation can lead to diverse pathological conditions, such as atherosclerosis, 55 cardiovascular disease, or development of tumours.
Similarly, and related to the ability of LPA to promote cell proliferation, the LPA 1 receptor is gaining attention as a druggable target for brosis. 56, 57 This disease involves the formation of excessive connective tissue, and it has been found to be strongly inuenced by receptor-mediated LPA signalling in lung, kidney and skin. Hence, increased epithelial cell apoptosis, migration and proliferation of lung broblasts, together with enhanced broblast resistance to apoptosis are LPA 1 -mediated processes directly linked to the development of pulmonary, dermal and kidney brosis. In addition, the results obtained with a dual LPA 1 /LPA 3 antagonist suggest a possible implication of the LPA 3 receptor. Supporting these data, one LPA 1 antagonist has entered phase II clinical trials for idiopathic pulmonary brosis (IPF) 58 and another one is in preclinical stages, indicated for the treatment of liver, lung and kidney brosis.
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Recent research has also associated the LPA 1 receptor with the initiation and development of rheumatoid arthritis (RA). It is known that synovial broblasts (SFs), implicated in the beginning and perpetuation of RA, express all LPA receptors and that LPA stimulates proliferation, adhesion and migration of SFs. Accordingly, the LPA 1 receptor has been suggested as a possible therapeutic target in the treatment of this disease.
60,61
LPA 1 is also the most widely expressed lysophospholipid receptor in adipose tissue, a fact that makes it an interesting pharmacological target for the treatment of obesity-associated metabolic diseases. Obesity, one of the key factors leading to type II diabetes, is accompanied by an increased ATX-mediated synthesis of LPA by adipocytes, where LPA exerts different biological actions through the activation of the LPA 1 receptor.
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Finally, it is well known that LPA signalling inuences cancer-related processes, 63 especially via LPA 2 . Nevertheless, there is also evidence of LPA 1 implication in cancer progression, specically in ovarian, breast and gastrointestinal ones.
LPA 1 receptor ligands
Given the importance of the LPA 1 receptor in a variety of pathologies, the need for potent and selective ligands is crucial to unravel its potential as a therapeutic target, but up to this moment there are no drugs in the market targeting any of the LPA receptors.
Although much research is ongoing in this eld, 64 the lack of potent and selective ligands is still an issue. Lipid-resembling molecules encounter solubility problems and show very high protein binding with only a small percentage within plasma available to interact with receptors. Moreover, the abundant cell surface lipid phosphate phosphohydrolases may rapidly degrade them. Regarding non-lipid structures, some advances have been done in the eld of antagonists, as two of them have currently reached clinical trials. 58, 65, 66 Still, small-molecule agonists structurally different from LPA have not been described yet.
Agonists of the LPA 1 receptor
Detailed studies have been carried out on the search for the essential patterns required to obtain selective agonism at the LPA 1 receptor. 40 The information available so far comes from LPA analogues, as no structurally different synthetic agonists have been described yet (Fig. 4   3 ). The rst LPA-based agonist was N-acyl ethanolamide phosphoric acid (2- 5 ) were carried out. These groups, especially phosphonates, had higher pK a values than LPA, so a-substituted phosphonates with electronegative groups at the a-carbon were also prepared in order to maintain acidity (Fig. 5, right panel improved it. It must be noted that analogue 8, bearing an a-uorophosphonate moiety, more acid than compound 5, was inactive at the LPA 1 receptor, indicating that acidity is not the only requirement for receptor activation when modifying the phosphate moiety. 70 In fact, other LPA-derived phosphonates and analogues bearing uoro or diuoro moieties in the acarbon act as good LPA 2 or LPA 3 agonists, but are inactive at LPA 1 .
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The LPA analogue (2S)-2-methoxy-3-(thiophosphonooxy) propyl (9Z)-octadec-9-enoate or OMPT (9) 3 agonists but also present modest activity at LPA 1 (Fig. 6) . 73 In order to prevent acyl chain migration, other metabolically stabilizing modications were carried out, leading to phosphorothioate analogues of sn-2-acyl LPA (compounds 12-14, Fig. 6 ). These three compounds displayed weak LPA 1 agonism, but they stand out as potent LPA 3 , LPA 5 and LPA 6 agonists.
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The inuence of the position of the acyl chain has also been studied. For example, sn-2 LPA derivatives resistant to acyl migration such as 1,1-diuorinated phosphates, 75 diuor-omethyl phosphates 76 or a-uorinated phosphonates 77 were synthesized. Unfortunately, none of these compounds was active at the LPA 1 receptor, 71 though LPA 1 and LPA 2 receptors were reported to show no regioisomeric preference between sn-1 and sn-2 positions.
Cyclic phosphate analogues have also been described as LPA 1 agonists (Fig. 7) . The cyclic diuorophosphate 15 was reported as a weak LPA [1] [2] [3] 78 In addition, some acetal phosphatidates, also known as Darmstoff analogues, have been reported as LPA mimetics. Some of these compounds are LPA pan-agonists (16) (17) (18) (19) , though with activity in the low micromolar range at the LPA 1 receptor. 79 Again, small structural modications turn the compounds into antagonists.
In summary, around 20 years aer the discovery of the rst LPA 1 ligands, there is still a lack of potent and selective agonists. Nowadays, the knowledge about the features needed for the activity has been somehow disclosed, but despite that, the complete puzzle of the structural requirements for activating this receptor is not yet fully understood.
Antagonists of LPA 1 receptor
The LPA 1 antagonist eld is a current focus of pharmaceutical companies. Structurally, LPA 1 antagonists can be classied into two broad classes: a family closely related to LPA and a second group formed by compounds whose structures widely differ from LPA. Starting with LPA analogues, modication of the agonist NAEPA (1, Fig. 5 ) with a bulky substituent in the b-carbon atom led to compound 20, which turned out to be a dual LPA 1 (Fig. 8) .
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Another important LPA analogue is bromophosphonate 24 (Fig. 9) 83 This molecule has contributed to elucidate the involvement of LPA receptors in the inhibition of tumour growth 84 and in the attenuation of arthritis in animal models.
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Cyclic LPA derivatives have also been described as LPA 1 antagonists (Fig. 10) Overall, these series of compounds show the difficulty of discovering the requirements needed to regulate the pharmacology of LPA-derived ligands, as subtle changes in their structures convert agonists into antagonists and cause drastic changes in activity. In addition, the coexistence of a polar head and a long hydrophobic tail becomes a problem in order to obtain orally active compounds. Thus, high-throughput screening was used to discover novel hits, structurally different from LPA, followed by hit to lead processes to improve their pharmacology.
The rst reported non-lipid dual LPA 1/3 antagonist was compound 28 (Ki16425, Fig. 11 (Fig. 13) .
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Further exploration of the central heterocycle ring by other pharmaceutical companies has led to potent antagonists of the Fig. 14) is an LPA 1 antagonist with an IC 50 value of 6.6 nM.
Initially inspired by Ki16425, Sano-Aventis synthesized a series of non-natural amino acids, such as compound 35 (Fig. 15) , with IC 50 values lower than 100 nM. It must be highlighted that SAR100842 (structure not yet disclosed) is an LPA 1 /LPA 3 antagonist from this set of compounds, which has completed phase II clinical trials for systemic sclerosis.
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In conclusion, it is clear that the LPA 1 receptor has an outstanding but yet intriguing role under physiological and pathological conditions. Thus, the discovery of potent and selective agonists and antagonists is nowadays a crucial need to achieve the validation of this receptor as a therapeutic target.
LPA 1 receptor ligands under clinical development
The implication of LPA in multiple diseases has attracted research interest from both academia and pharmaceutical companies in order to validate the LPA pathway as a source of novel druggable targets. Focusing on the LPA 1 receptor, preclinical results obtained from LPA 1 knockout mice and the use of specic antagonists in animal disease models have demonstrated the key role of this receptor in mediating the pro-brotic effects of LPA in broblasts. Therefore, the challenge remains to prove that LPA 1 antagonists could be developed as effective therapeutics for the treatment of brotic disorders, such as IPF, hepatic brosis and systemic sclerosis. To date, two LPA 1 antagonists, BMS-986020 and SAR100842, have advanced into clinical investigation for the treatment of IPF 58 and systemic sclerosis. 66 Furthermore, an orally bioactive small-molecule LPA 1 antagonist developed by Angion is at a preclinical stage for the treatment of liver, lung and kidney brosis.
59
BMS-986020, initially developed by Amira and then by Bristol-Myers Squibb, has recently completed a phase I study to assess the pharmacokinetics, metabolism and excretion, as well as safety and tolerability of a single oral dose. Moreover, a single sequence study has also been conducted to evaluate the effect of concomitant administration of BMS-986020 on the pharmacokinetics of rosuvastatin. Currently, two new clinical trials are recruiting participants: a phase I study to evaluate the relationship between plasma drug levels and receptor binding in the lungs using positron emission tomography (PET); and a phase II trial to determine if once or twice daily administration of 600 mg of BMS-986020 will reduce the decline in the forced vital capacity and will be tolerated well in subjects with IPF. Additionally, a phase I study to assess the drug-drug interaction in healthy volunteers is announced to start in September 2014. This study will determine the effect of BMS-986020 on the pharmacokinetics of montelukast, urbiprofen, and digoxin.
Sano-Aventis has conducted a phase II trial with the dual LPA 1 /LPA 3 antagonist SAR100842 to evaluate its safety and tolerability in an 8 week study in patients with diffuse, cutaneous systemic sclerosis. 66 This clinical study was completed in April 2014 and the results have not been reported yet.
In summary, the progression of LPA 1 antagonists into clinical trials will hopefully help to ascertain the therapeutic utility of the LPA 1 receptor as a novel target for the treatment of disorders with high unmet medical need such as IPF. Outlook and future perspectives
Lipid-binding GPCRs are potential drug targets for many diseases including neuropshychiatric and neurodegenerative disorders, multiple sclerosis, pain, inammation-related diseases, and cancer. In particular the LPA 1 receptor plays fundamental roles in both the central and the peripheral nervous system. However, the paucity of currently available potent and selective (ant)agonists for the different LPA receptors is hampering the validation of this receptor as a therapeutically useful target. In this regard, some advances have been made in terms of the development of antagonists, some of which are currently undergoing clinical trials. However, the eld of agonists is still clearly lagging behind as not really potent and selective agents structurally different from LPA have been disclosed. In addition, it is likely that the progress in structural determination of GPCRs will extend also to LPA receptors, and structures of these receptors in complex with different ligands can be elucidated in the upcoming future. These advances should also consider the importance of biased and allosteric ligands, since they can help to unravel the biology behind these receptors and to provide new therapeutic solutions for important diseases that lack adequate clinical treatments today. 
